课题基金 / 基金详情

Novel bifunctional antiandrogens that suppress oncogenic activation of the androgen receptor in castration-resistant prostate cancer

Novel bifunctional antiandrogens that suppress oncogenic activation of the androgen receptor in castration-resistant prostate cancer
新型双功能抗雄激素可抑制去势抵抗性前列腺癌中雄激素受体的致癌激活
批准号：
206036
负责人：
Wu Jian Hui
金额：
$11.64万
依托单位：
CIUSSS de Centre-Ouest-de-l'Ile-de-Montral-Jewish General
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2010
资助国家：
加拿大
项目状态：
已结题
起止时间：
2010-03-01 至 2011-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=206036&lang=en
关键词：
Androgen Receptor Antiandrogen Castration-Resistant Prostate Cancer Ikk Mutation

项目摘要

项目成果

Wu Jian Hui的其他基金

相似基金

相关文献

中文摘要
翻译
在加拿大和美国，每年有超过3万男性死于前列腺癌。前列腺癌细胞的生长严重依赖于雄激素受体（AR）信号。目前治疗早期或晚期前列腺癌的主要方法是抑制AR激活
英文摘要
Over 30,000 men die from prostate cancer in Canada and USA each year. Prostate cancer cell growth is critically dependent on the androgen receptor (AR) signaling. Current mainstay treatment for early or advanced prostate cancer aims to suppress AR activat
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Repurposing of FDA-approved drugs as novel therapeutics for COVID-19
Development of novel pan-inhibitors of the androgen receptor variants as effective therapeutics for castration-resistant prostate cancer
Chemical inhibitors of androgen receptor splice variants lacking the ligand-binding domain as novel agents for castration-resistant prostate cancer
海外基金